Original Publication Date: 1 January, 2015
Publication / Source: Future Oncology
Authors: Alfredo Tartarone
A major area of controversy in the management of advanced non-small-cell lung cancer (NSCLC) is the role of maintenance therapy. Widely used in the treatment of other solid tumors and hematologic malignancies, maintenance therapy has become a treatment paradigm also for advanced NSCLC only recently due to the introduction in clinical practice of more tolerable drugs, such as pemetrexed, bevacizumab or erlotinib and on the basis of clinical data coming from large Phase III randomized trials.